Sigut
Sigut

Simplifying AMPylation research: Making pro-N6pA commercially available

AMPylation, a critical protein post-modification process, is gaining significant research interest. Yet, a major roadblock existed – the lack of a readily available probe molecule for studying this process. This case study explores how Sigut Labs tackled this challenge by making N6-propargyl adenosine phosphoramidate (pro-N6pA) commercially accessible, paving the way for more efficient AMPylation research.

Background information

Researchers from the Technical University of Munich and Max Planck Institute of Psychiatry, Munich, Germany recently reported (Nat Commun 11, 517 (2020)) novel N6-propargyl adenosine phosphoramidate (pro-N6pA). This innovative compound offers a simplified approach to identifying proteins undergoing AMPylation, a crucial protein post-translational modification (PTM) involved in the modulation of neurodevelopment and neurodegeneration (Cell Chemical Biology, 27(7), 773-779).

Pro-N6pA’s effectiveness lies in its ability to enter cells readily and undergo metabolic activation. Once inside, it transforms into N6pATP, a molecule accepted by AMP-transferases, the enzymes responsible for the AMPylation of proteins.

SigutLabs_Figure 1_Structure of pro-N6pA synthesized at SigutLabs
Figure 1_Structure of pro-N6pA synthesized at SigutLabs

Identifying the issue

Sigut Labs was contacted by Dr. Pavel Kielkowski, one of the inventors of the molecule, to inquire about our ability to prepare it on a larger scale. At their lab at the TU Munich Munich and later LMU Munich, pro-N6pA was typically prepared on a milligram (mg) scale solely for their internal research. This meant that any researcher needing pro-N6pA for their application had to synthesize it themselves.

While the synthesis is well-described with several preparation options available, it remains time-consuming and requires a skilled synthetic chemist along with appropriate laboratory equipment for handling sensitive compounds.

Additionally, many scientists from various academic institutions worldwide were contacting Dr. Kielkowski to request pro-N6pA for their studies.

Methodology insight

Equipped with the necessary skills and advanced equipment, Sigut Labs’ team of experienced chemists tackled the challenge of large-scale pro-N6pA production. Here’s how we achieved it:

  • Pathway evaluation: We scrutinized existing and novel synthetic pathways for pro-N6pA.
  • Optimization and scale-up: The most promising route was selected and optimized, enabling multigram quantities within just two weeks.
  • Exceptional purity: The synthesized pro-N6pA exceeded 99% purity, verified through advanced analytical techniques including 1H-NMR, 31P-NMR, and LC-MS.

Positive outcome

Sigut Labs’ collaboration with the Kielkowski Research Group has resulted in the successful large-scale production of pro-N6pA. This accomplishment offers significant benefits to the scientific community:

  • Increased availability: Researchers can now access pro-N6pA readily, eliminating the need for in-house synthesis and saving valuable time and resources.
  • Simplified research: Ready-made pro-N6pA facilitates a quicker start to AMPylation research projects.
  • Consistent quality: Sigut Labs’ expertise ensures consistent quality and purity of pro-N6pA, leading to reliable research data.

By making pro-N6pA commercially available, we significantly empowered the research community with a key tool for AMPylation studies.

"Sigut Labs' ability to rapidly adapt and optimize the synthesis process was impressive. They efficiently scaled up production and delivered gram quantities within weeks. I am convinced that making pro-N6pA commercially available through Sigut Labs will significantly benefit the scientific community by simplifying access to this vital research tool."

Dr. Pavel Kielkowski, research group leader at LMU

SigutLabs_Foto Pavel Kielkowski

Need high-purity pro-N6pA for your next AMPylation project? Visit our e-shop.

OUR CASE STUDY

Scale-up to accelerate drug discovery

Our experience helped overcome development hurdles for potential cancer & mental health drugs.

Read more

Empowering neuro research with pro-N6pA

Sigut Labs scaled up pro-N6pA production, simplifying AMPylation research & boosting accessibility.

Read more

ADC development leaps with new linkers

Novel linker design expedited ADC advancement, leading to promising lead compounds faster.

Read more

Lincomycin derivative scale-up

Over 30 g of the desired product with exceptional purity was obtained through our optimized procedure.

Read more

Purifying 350 kg of vitamin K2 oil

Our innovative scale-up technology helped to reduce the client’s purification process from days to hours.

Read more

Our services

What we excel in so you don’t have to

View more
Thumbnail image Custom synthesis

Custom synthesis

Providing for a custom synthesis of previously reported molecules using described synthetic procedures.

Thumbnail image Contract research

Contract research

Developing novel synthetic routes to provide undescribed compounds in organic, bioorganic, and medicinal chemistry.

Thumbnail image Scale-Up

Scale-Up

Helping you go from lab scales to an industrial scale by applying our cutting-edge instrumentation.

Contact
Kryštof

Get in touch

Krystof Sigut, CEO and Founder
arrow

Our Experts

Profile image Krystof Sigut
Krystof Sigut
- CEO and Founder -
International chemical practitioner eager to restore Czech chemistry's global prestige. Contact Krystof for inquiries, NDA signing, or business matters.
Profile image Petr Slavik
Petr Slavik
- Head of Chemistry -
Synthetic chemistry pro with a decade's diverse lab expertise. For offers, research discussions, or detailed insights, reach out to Petr directly.

Partners & distributors

logo partner
logo partner
logo partner
logo partner
logo partner
logo partner
logo partner
logo partner
logo partner
logo partner
logo partner
logo partner